Physician profile
James B Baker
NPI 1225086630
$4,137.88
in general payments reported to CMS, 2019-2025
50 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $556 · 2021: $1,068 · 2022: $478 · 2023: $410 · 2024: $799 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $807.13 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $370.42 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $229.16 | 2019-2025 | Breztri |
| Dexcom, INC. | $214.16 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $201.50 | 2020-2022 | |
| Astellas Pharma US INC | $189.46 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $173.87 | 2021-2022 | |
| Esperion Therapeutics, INC. | $124.46 | 2021 | |
| Pfizer INC. | $123.03 | 2019-2021 | |
| Abbott Laboratories | $121.71 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $110.28 | 2021-2024 | |
| Amgen INC. | $109.88 | 2022-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $105.19 | 2020-2025 | Fruzaqla, Vonvendi, Gattex |
| Eisai INC. | $94.54 | 2021-2024 | |
| Janssen Biotech, INC. | $82.39 | 2023-2025 | Darzalex, Carvykti, Talvey |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.